| Date | Title | Description |
| 20.10.2025 | Kardigan: $254 Million Series B Closed To Advance Late-Stage Portfolio Of Personalized Cardiovascular Medicines | Kardigan, a biotechnology company focused on redefining cardiovascular drug development, announced the successful closing of a $254 million Series B financing round. The funding round featured participation from new investors, including Fid... |
| 16.10.2025 | Pelage Pharmaceuticals: $120 Million Series B Raised For Advancing Regenerative Medicine Hair Loss Treatment | Pelage Pharmaceuticals, a Los Angeles–based biotechnology company developing regenerative treatments for hair loss, announced the close of a $120 million Series B financing round co-led by ARCH Venture Partners and GV (Google Ventures). The... |
| 15.10.2025 | Kardigan: $254 Million Series B Secured To Advance Late-Stage Cardiovascular Medicines | Kardigan, a biotechnology company focused on modernizing cardiovascular drug development, announced it has raised $254 million in a Series B funding round to accelerate its late-stage portfolio of personalized medicines targeting heart dise... |
| 15.10.2025 | Pelage Pharmaceuticals Raises $120M in Series B Financing | Pelage Pharmaceuticals, a Los Angeles, CA-based clinical-stage regenerative medicine biotechnology company, closed a $120m Series B financing.
The round was co-led by ARCH Venture Partners and GV (Google Ventures), with participation from e... |
| 15.10.2025 | Kardigan Raises $254M in Series B Funding | Kardigan, a South San Francisco, CA- and Princeton, New Jersey-based heart health company modernizing cardiovascular drug development, closed a $254m Series B financing.
Backers included Fidelity Management & Research Company, accounts ... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 19.09.2025 | T.Rx Capital: $77.5 Million Fund I Launched To Invest In Startups | T.Rx Capital, a newly formed venture capital firm dedicated to early-stage healthcare innovation, has announced the close of its first fund, T.Rx Capital Fund I, at $77.5 million. The fund is focused on supporting visionary founders who are... |
| 03.09.2025 | Treeline Biosciences: $200 Million Additional Funding Raised And First Clinical Trials Announced | Treeline Biosciences, a company at the forefront of innovative cancer research, recently announced significant progress in its clinical development. They have started Phase 1 trials for three promising programs, two of which are internally ... |
| 05.08.2025 | iBIO Releases Inaugural Member Investor Portfolio Report Showcasing $1.24 Billion in Illinois Life Sciences Investment | Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030
CHICAGO, Aug. 5, 2025 /PRNewswire-PRWeb/ -- The Illinois Biotechnology Innovation Organization (iBIO)... |
| 24.07.2025 | Dispatch Bio Raises Series A in Funding; Total To $216M | Dispatch Bio, a San Francisco, CA- and Philadelphia, PA-based Biotechnology company developing treatments for tumours, raised an undisclosed amounting Series A funding.
Backers included ARCH Venture Partners and PICI, along with Bristol Mye... |
| 11.07.2025 | Centivax Secures $45M to Revolutionize Global Immunity | Centivax closed an oversubscribed $45 million Series A funding round. Future Ventures led the investment. This capital fuels the advancement of Centivax’s lead universal flu vaccine candidate. The vaccine will enter Phase I clinical trials ... |
| 10.07.2025 | Centivax: $45 Million Series A Raised For Advancing Universal Flu Vaccine | Centivax, a biotech firm developing vaccines and therapies for long-lasting, universal protection against diverse targets, announced it has closed an oversubscribed $45 million Series A funding round. Steve Jurvetson of Future Ventures led ... |
| 08.07.2025 | NUS Enterprise appoints global innovation experts to advance innovation and research translation efforts | SAN FRANCISCO, July 8, 2025 /PRNewswire/ -- NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS), has appointed Dr Patrick Ennis and Ms Donna See as strategic advisors to support its next phase of growth in ... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 08.05.2025 | Atlas: $155 Million Seed Financing And Acquisition Of Assets From Twist Bioscience | Atlas Data Storage – a technology company building end-to-end DNA data storage – announced the closing of a $155 million seed financing and the acquisition of technology assets from Twist Bioscience. The seed funding investors are ARCH Vent... |
| 06.05.2025 | The Future of Data Storage: Atlas Data Storage's Bold Leap into DNA Technology | In the world of technology, innovation is the lifeblood that fuels progress. Atlas Data Storage, a fledgling company based in South San Francisco, has just secured a staggering $155 million in seed funding. This financial boost marks a sign... |
| 05.05.2025 | Atlas Data Storage Raises $155M in Seed Funding | Atlas Data Storage, a South San Francisco, CA-based technology company building end-to-end DNA data storage solutions, raised $155m in seed financing.
Backers included ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capi... |
| 31.03.2025 | Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development | 3 Shares Email Facebook Twitter LinkedIn
Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process.
The new round was led by ... |
| 23.01.2025 | MGX’s AI Role In The US Grows | 2 Shares Email Facebook Twitter LinkedIn
While most of the talk about the White House’s new Stargate Project centered on the three big tech names — OpenAI, SoftBank and Oracle — Abu Dhabi-based investment firm MGX also is poised to play a b... |
| 15.01.2025 | Colossal Raises $200M in Series C Funding | Colossal Biosciences, a Dallas, TX-based de-extinction company, raised $200M in Series C Funding.
Backers included TWG Global. Other investors included USIT, Animal Capital, Breyer Capital, At One Ventures, In-Q-Tel, BOLD Capital, Peak 6, D... |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases |
RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 13.01.2025 | RhyGaze Closes USD 86M Series A Funding | RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding.
The round was led by GV (Google Ventures), alongside Arch Venture Partners, ... |
| 13.01.2025 | RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases | RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-... |
| 08.01.2025 | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
By ReutersJanuary 7, 202511:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The Nasdaq logo is displayed at the Nasdaq Mark... |
| 19.12.2024 | bit.bio raises $30 Million led by M&G Investments | bit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets.
Jonathan Milner appointed Interim CEO; Mark Kotter assumes Vice Chairman role as Company expands Board with d... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 22.11.2024 | Metsera: $215 Million (Series B) Raised To Develop Medicines For Obesity And Metabolic Diseases | Metsera – a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases – announced the closing of a $215 million Series B funding round to further advance its portfolio of highl... |
| 14.11.2024 | Metsera Raises $215M in Series B Financing | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $215M in Series B funding.
The round was led by Wellington Management and Venrock, with participation from Fidelity Management and Research Company, Janus Henderson Inves... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 09.10.2024 | Rippl: Virtual Dementia Care Company Raises $23 Million (Series A) | Rippl, a leader in virtual dementia care, announced the closing of its Series A funding round. Tina Hoang-To (Kin Ventures Founding General Partner) led the $23 million round with participation from Rippl’s seed investors ARCH Venture Partn... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 02.10.2024 | Rippl Secures $23M to Expand its Virtual Dementia Care Platform | What You Should Know:
– Rippl, a provider of virtual dementia care raises $23M ina Series A funding round led by Tina Hoang-To, Founding General Partner at Kin Ventures, with participation from existing investors including ARCH Venture Part... |
| 01.10.2024 | The 10 Biggest Rounds Of September: Safe Superintelligence’s $1B Raise Reigns Supreme | 1 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down the month’s top 10 funding rounds in the U.S. Check out the biggest rounds of last month here.
Lots of big rounds as summer fades into fall. AI startup Safe S... |
| 28.09.2024 | ARCH Venture Partners: $3+ Billion New Fund Raised To Invest In Next-Gen Biotech Companies | ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies.
ARCH invests in early-stage companies that prevent... |
| 26.09.2024 | ARCH Venture Partners Closes Over $3 Billion Biotech Fund | ARCH Venture Partners, a Chicago, IL-based venture capital firm, closed ARCH Venture Fund XIII, at more than $3 billion.
The vehicle will support the founding and growth of early-stage biotechnology companies. ARCH founds and invests in ear... |
| 26.09.2024 | ARCH Venture Partners raises $3 billion for a new biotech fund | - |
| 09.09.2024 | Пионер ксенотрансплантации eGenesis собрал $191 млн для генно-редактированных органов свиньи | Компания eGenesis уже попала в заголовки новостей благодаря трансплантации органов свиньи. В марте 2024 года eGenesis объявила о первой в мире успешной пересадке почки свиньи живому пациенту. Трансплантация была одобрена FDA в рамках расшир... |
| 09.09.2024 | Стартап в сфере клеточной терапии ArsenalBio привлек $325 млн | В раунде финансирования Arsenal Biosciences приняли участие новые инвесторы ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (венчурное подразделение NVIDIA), Luma Group, фонды, консультируемые T. Rowe Price... |
| 05.09.2024 | A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China | SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in ... |
| 04.09.2024 | eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages | eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici... |
| 04.09.2024 | ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs | Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round.
This fund... |
| 04.09.2024 | eGenesis Raises $191M in Series B Funding | eGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding.
The round was led by Lux Capital, with participation from existing i... |
| 04.09.2024 | ArsenalBio Raises $325M in Series C Funding | ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding.
The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, fu... |
| 19.08.2024 | Quantum Circuits: Yale Computing Solution Spinout Raises Over $60 Million (Series B) | Quantum Circuits announced it has secured a final Series B investment round of over $60 million. This funding round provides additional capital support as it prepares to commercialize its quantum systems with an industry first: error detect... |
| 30.07.2024 | The New Frontier in Biotech: Partnerships and Innovations Shaping the Future of Medicine | In the ever-evolving landscape of biotechnology, partnerships are the lifeblood of innovation. Two recent collaborations highlight this trend: GSK's partnership with Flagship Pioneering and Autobahn Therapeutics' successful funding round. B... |
| 29.07.2024 | Autobahn Therapeutics: $100 Million Raised To Develop Restorative Treatments For Depression and Other CNS Disorders | Autobahn Therapeutics (a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders) announced the closing of an oversubscribed $100 million Series C funding led by Newpath... |
| 25.07.2024 | Highlands and Paradigm improve access to cancer care options in northwest Arkansas, increasing clinical trial participation by 45% | COLUMBUS, Ohio and FAYETTEVILLE, Ark., July 25, 2024 /PRNewswire/ -- Paradigm and Highlands Oncology announce promising results from their ongoing collaboration, demonstrating a 45% increase in the number of patients enrolled in clinical tr... |
| 15.05.2024 | Most-Active US Investors: Sequoia, Khosla, General Catalyst Lead Strong Pack In April | 9 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 30.04.2024 | Rippl acquires Kinto | Rippl, a Seattle, WA-based dementia-focused specialty care provider, announced it has acquired Kinto, a Boston, MA-based provider of an AI-enabled dementia caregiver support platform.
The amount of the deal was not disclosed.
This combinati... |
| 25.04.2024 | Xaira Therapeutics: A Billion-Dollar Bet on AI Drug Discovery | In the fast-paced world of tech and biotech, Xaira Therapeutics emerges as a powerhouse with a massive $1 billion in funding. Led by CEO Marc Tessier-Lavigne, a former Stanford president and Genentech chief scientific officer, Xaira is read... |
| 24.04.2024 | Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs | Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery.
On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of... |
| 12.04.2024 | Most-Active US Investors: General Catalyst Tops March’s List | 3 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 02.04.2024 | Autism Impact Fund closes $60M first fund and broadens its scope | Millions of people around the world are affected by autism spectrum disorder (ASD). Both as kids and later in life, these individuals and their families need better detection, treatment and support solutions that will help them live with au... |
| 02.02.2024 | ARCH Venture Partners is raising $3 billion for a life sciences fund | ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake... |
| 25.07.2023 | Molecular farming: IngredientWerks grows heme protein in corn at ‘unprecedented low cost’ | Molecular farming startup IngredientWerks has genetically engineered corn crops to express high levels of bovine myoglobin in a process it claims can scale at a fraction of the cost of precision fermentation.
A heme-binding protein found in... |
| 11.04.2023 | Recuro Health Closes $47 Million Series B Financing Led by ARCH Venture Partners, Advancing Innovative Virtual-First Care Service | DALLAS–(BUSINESS WIRE)–April 11, 2023–
Recuro Health (Recuro), an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused model to a proactive care approach, today annou... |
| 07.03.2023 | ARCH leads Volastra $60 million financing round | - |
| 27.01.2023 | Paradigm Launches with $203M to Improve Clinical Research Access | What You Should Know:
Paradigm’s financing was co-led by ARCH Venture Partners and General Catalyst and joined by funds including F-Prime Capital, GV, LUX Capital, Mubadala Capital, and Magnetic Ventures, and strategic investors including t... |
| 28.09.2022 | Rippl Launches with $35M to Transform Mental Health for Seniors | What You Should Know:
Mental and behavioral health for seniors is a massive hidden public health crisis. The total national cost of care for dementia patients, including those with Alzheimer’s disease, is projected to be $321 billion in 202... |
| 20.09.2022 | Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies | What You Should Know:
Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondri... |
| 29.08.2022 | Sneaky synthetic molecules open the way for new types of drugs and a new startup | An illustration shows how custom-made peptide molecules (shown in pink and purple) can slip through a cell membrane. (Image by Ian C. Haydon / UW Institute for Protein Design)
Researchers at the University of Washington have discovered how ... |
| 29.06.2022 | ARCH Venture Partners Announces $2.975 Billion Fund XII to Create and Fund Early Stage Biotechnology Companies | - |
| 29.06.2022 | Arch Venture Partners Closes Fund XII, at $2.975 Billion | Arch Venture Partners, a Chicago, IL-based venture capital firm, closed Arch Venture Fund XII, at $2.975 billion.
The fund will invest in the creation, development and funding of early stage biotechnology companies with potential to solve s... |
| 29.06.2022 | ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn | - |
| 29.06.2022 | 'Science doesn't care' about markets: Arch raises nearly $3B amid tough times for biotechs | Arch Venture Partners is out to prove there’s still money for the taking for up-and-coming biotechs, raising nearly $3 billion for its latest fund amid a tumultuous bear market.
The company was relatively vague on what the money for its twe... |
| 19.05.2022 | Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! | Concept of a healthy female reproductive system. getty |
| 14.04.2022 | ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer | - |
| 20.01.2022 | ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital | ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced the closing of a $75 million Series B financing. The round was led by ARCH V... |
| 20.01.2022 | Super-resolution microscope maker ONI nabs $75M for US expansion, Series B led by ARCH Venture | - |
| 14.09.2021 | BREAKING: AgBiome closes $116m Series D round led by Blue Horizon, Novalis LifeSciences | US-based crop protection products company AgBiome has raised $116 million in a Series D funding round co-led by Blue Horizon Ventures and Novalis LifeSciences.
Additional participants included new and incumbent investors such as Bayer, Fide... |
| 14.09.2021 | AgBiome closes $116m Series D round led by Blue Horizon, Novalis LifeSciences | US-based crop protection products company AgBiome has raised $116 million in a Series D funding round co-led by Blue Horizon Ventures and Novalis LifeSciences.
Additional participants included new and incumbent investors such as Bayer, Fide... |
| 25.08.2021 | Recuro Health Announces Its $15 Million Series A Round Led by ARCH Venture Partners | - |
| 30.07.2021 | DA32 Life Science Tech Acquisition Corp. : Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering | DA32 Life Science Tech Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Class A common stock began trading on The N... |
| 28.07.2021 | DA32 Life Science Tech Acquisition Corp. : Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering | DA32 Life Science Tech Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Class A common stock are expected to be lis... |
| 26.07.2021 | The Trump crackdown hits the SPAC world | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
A close advisor to former President Donald Trump and one of his top fundraisers in 2016, private ... |
| 26.04.2021 | With a third of its capital deployed, Risk & Return is transforming how we think about emergency response | Disasters are, unfortunately, a growth business, and the frontlines that were once distant have moved much closer to home. Wildfires, hurricanes, floods, tornadoes — let alone a pandemic — has forced much of the United States and increasing... |
| 29.01.2021 | Arch raises $1.9B to build another crop of breakthrough biotechs | Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.
Sponsored by Agilent Technologies
How would you like to wi... |
| 29.01.2021 | Arch raises $1.9B to build another crop of breakthrough biotechs | Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.
As with its earlier funds, Arch will use the money to plac... |
| 28.01.2021 | Arch Venture Partners Closes $1.85 Billion Fund | Chicago, IL-based venture capital firm Arch Venture Partners closed Arch Venture Fund XI, at over $1.85 billion.
The new fund will invest in the creation and funding of early stage biotechnology companies.
Arch will invest Fund XI in early ... |
| 28.01.2021 | ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies | |
| 28.01.2021 | ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies | - |
| 04.04.2020 | ARCH Venture Partners Closes $1.46 Billion For Two Funds | ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture Fund X Overage at $1.46 billion
ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture ... |
| 02.04.2020 | ARCH Venture Partners Announces $1.46 Billion Raised in Two New Funds to Invest in Transformative Biotechnology Companies | - |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
| 02.04.2020 | Arch raises $1.5B to back early-stage biotechs through accelerating 'healthcare revolution'
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the money across two funds that will deploy cash to help ... |
| 02.04.2020 | ARCH Venture Partners Raises $1.5B Over 2 Funds to Back Biotech Companies | As the coronavirus crisis worsens throughout the U.S., a Chicago venture firm just raised nearly $1.5 billion in two new funds to back companies fighting against COVID-19 and other health care challenges.
ARCH Venture Partners announced Thu... |
| 02.04.2020 | ARCH Venture Partners raises $1.46 billion across two funds for biotech investing | Against a backdrop where the life-or-death consequences of biotechnology innovation are becoming increasingly apparent as the world races to develop vaccines and therapies to treat COVID-19, life sciences investor ARCH Venture Partners has ... |
| 02.04.2020 | Arch raises $1.5B to back early-stage biotechs through accelerating 'healthcare revolution' | Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the money across two funds that will deploy cash to help ... |
| 02.04.2020 | Arch Venture Partners Closes Two New Funds, at $1.46 Billion | Chicago, IL-based ARCH Venture Partners closed two new funds, with a combined $1.46 billion.
Limited partners include endowments, family offices, sovereign wealth funds and other institutional investors.
ARCH Venture Fund X and ARCH Venture... |
| 08.05.2019 | LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform | LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The lates... |
| 22.03.2019 | 11 Under-The-Radar Chicago VCs You Should Know About | In my most-recent Forbes article, I shared about 12 Chicago-based VCs that are behind hot startups both within our region, like G2 Crowd, and beyond, like SpaceX. These firms tend to get a lot of buzz and make national headlines, but they a... |
| 30.10.2018 | Arch Venture sets its sights on raising $600M for Fund X | Bob Nelsen
Bob Nelsen’s VC group Arch Venture Partners has filed paperwork with the SEC expressing its plans to raise $600 million for its tenth fund — its biggest ever. The announcement comes at a time when the biopharma world i... |
